4D Molecular Therapeutics (FDMT) Return on Equity (2021 - 2025)
Historic Return on Equity for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to 0.53%.
- 4D Molecular Therapeutics' Return on Equity fell 2800.0% to 0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53%, marking a year-over-year decrease of 2800.0%. This contributed to the annual value of 0.39% for FY2024, which is 200.0% down from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Return on Equity of 0.53% as of Q3 2025, which was down 2800.0% from 0.44% recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Return on Equity registered a high of 0.18% during Q2 2024, and its lowest value of 0.53% during Q3 2025.
- Moreover, its 5-year median value for Return on Equity was 0.3% (2024), whereas its average is 0.33%.
- Its Return on Equity has fluctuated over the past 5 years, first skyrocketed by 2600bps in 2024, then plummeted by -2800bps in 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Return on Equity (Quarter) stood at 0.26% in 2021, then tumbled by -70bps to 0.45% in 2022, then grew by 29bps to 0.32% in 2023, then increased by 4bps to 0.3% in 2024, then tumbled by -75bps to 0.53% in 2025.
- Its Return on Equity stands at 0.53% for Q3 2025, versus 0.44% for Q2 2025 and 0.36% for Q1 2025.